Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
| Autor: | Janjigian, Yelena Y *, Kawazoe, Akihito, Bai, Yuxian, Xu, Jianming, Lonardi, Sara, Metges, Jean Phillipe, Yanez, Patricio, Wyrwicz, Lucjan S, Shen, Lin, Ostapenko, Yuriy, Bilici, Mehmet, Chung, Hyun Cheol, Shitara, Kohei, Qin, Shu-Kui, Van Cutsem, Eric, Tabernero, Josep, Li, Kan, Shih, Chie-Schin, Bhagia, Pooja, Rha, Sun Young |
|---|---|
| Zdroj: | In The Lancet 9-15 December 2023 402(10418):2197-2208 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|